Skip to main content
Midas Edge

Passage BIO, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

PASG$3.78+10.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​​
​ · ​ · Common stock · ​ · ​ · Additional · ​ · ​ · Accumulated other · ​ · ​ · Accumulated · ​ · ​ · ​
(in thousands, except share data)​ ​ ​Shares​ ​ ​​Amount​ ​ ​​ ​ ​paid‑in capital​​comprehensive income (loss)​​ ​ ​deficit​​Total
Balance at July 1, 20263,217,810​$—​$724,593​$—​$(720,137)​$4,456
Exercise of stock options and vesting of restricted stock units—​​—​​—​​—​​—​—
Share‑based compensation expense—​​—​​313​​—​​—​313
Net loss—​​—​​—​​—​​(4,719)​(4,719)
Balance at September 30, 20263,217,810​$—​$724,906​$—​$(724,856)​$50
​​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​​
​​Common stock​​Additional​​Accumulated other​​Accumulated​​​
(in thousands, except share data)​ ​ ​Shares​ ​ ​​Amount​ ​ ​​ ​ ​paid‑in capital​​comprehensive income (loss)​​ ​ ​deficit​​Total
Balance at January 1, 20263,182,810​$—​$723,512​$—​$(704,757)​$18,755
Exercise of stock options and vesting of restricted stock units35,000​—​—​—​—​—
Share‑based compensation expense—​—​1,394​—​—​1,394
Net loss—​—​—​—​(20,099)​(20,099)
Balance at September 30, 20263,217,810​$—​$724,906​$—​$(724,856)​$50

Consolidated Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​​
​ · ​ · Common stock · ​ · ​ · Additional · ​ · ​ · Accumulated other · ​ · ​ · Accumulated · ​ · ​ · ​
(in thousands, except share data)​Shares​​Amount​​paid‑in capital​​comprehensive income (loss)​​ ​ ​deficit​​Total
Balance at July 1, 2025​ ​ ​3,178,710​$—​$722,283​$—​$(684,025)​$38,258
Share‑based compensation expense​—​​—​​611​​—​​—​​611
Net loss—​​—​​—​​—​​(7,749)​​(7,749)
Balance at September 30, 2025​3,178,710​$—​$722,894​$—​$(691,774)​$31,120
​​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​​
​​Common stock​​Additional​​Accumulated other​​Accumulated​​​
(in thousands, except share data)​ ​ ​Shares​​Amount​​paid‑in capital​​comprehensive income (loss)​​ ​ ​deficit​​Total
Balance at January 1, 20253,161,503​$—​$720,488​$8​$(659,235)​$61,261
Exercise of stock options and vesting of restricted stock units​14,325​​—​​—​​—​​—​​—
Issuance of shares in connection with employee stock purchase plan​2,882​​—​​14​​—​​—​​14
Unrealized gain (loss) on marketable securities​—​​—​—​​(8)​​—​​(8)
Share‑based compensation expense—​​—​​2,392​​—​​—​​2,392
Net loss—​​—​​—​​—​​(32,539)​​(32,539)
Balance at September 30, 20253,178,710​$—​$722,894​$—​$(691,774)​$31,120

See accompanying notes to unaudited interim consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.